PET-Negative After Three Cycles: Whether to Stop There
Her interim scan came back clean. Whether that clean scan means she's done, or means radiation should still finish the job, turned out to be a question the trial that studied it never fully settled either.
Priya D. is four months from a wedding she has been planning in obsessive, color-coded detail since the engagement, a project her fiancé describes as her second full-time job on top of her actual one in marketing. She is 26, diagnosed with early-stage (IA) classical Hodgkin lymphoma with mediastinal involvement after a persistent cough led to a chest X-ray neither she nor her doctor expected to be abnormal. She completed three cycles of ABVD, timed carefully around her work calendar, and her interim PET scan came back Deauville score 2 — unambiguously negative.
That result puts her in the specific population the RAPID trial was built to study: early-stage favorable Hodgkin, chemotherapy-responsive, facing the actual decision of whether consolidation radiotherapy adds enough benefit to justify its own long-term cost. RAPID randomized exactly this population to no further therapy versus consolidation radiotherapy after a PET-negative interim scan, and found a real difference in progression-free survival favoring radiotherapy, without a corresponding difference in overall survival — relapses in the no-radiotherapy arm were, for the most part, salvageable.
For a 26-year-old with decades of life ahead of her, and a wedding four months out she has every intention of walking into without a fresh course of radiation hanging over her recovery, weighing a modest increase in relapse risk against mediastinal radiation's own cumulative, well-documented long-term risks to the heart, breast tissue, and thyroid is not an abstract statistics exercise. It's the actual shape of the decision in front of her, and it's one RAPID's own authors were candid did not resolve cleanly in either direction.
A clean scan, and what to do with it
Consolidation involved-site radiotherapy is the evidence-supported choice here. RAPID randomized this exact population — early-stage favorable Hodgkin, PET-negative after ABVD — and found a real improvement in progression-free survival with radiotherapy — fewer relapses, not more — even though overall survival came out equivalent between arms. Relapse isn't a neutral event; it means salvage chemotherapy, possibly transplant, with real morbidity of its own.
Overall survival was equivalent. That's the number that matters most for a 26-year-old with fifty or more years of life ahead of her. Mediastinal radiation carries well-documented, cumulative lifetime risk — breast cancer, coronary artery disease, hypothyroidism — that compounds over decades in a way a same-year relapse-rate comparison doesn't capture.
If she relapses without radiotherapy, relapsed Hodgkin remains highly curable with salvage therapy. The cost of omission is a higher chance of retreatment, not a survival cost. For someone her age, minimizing decades of cumulative toxicity should be the starting frame, not an afterthought weighed against a PFS curve.
The long-term toxicity data you're citing is real, and I'm not disputing it existed.
But most of it reflects older mantle-field radiation technique, delivering radiation dose across a much wider field than what we'd actually use today. Modern involved-site radiotherapy with conformal planning substantially reduces incidental dose to the heart and breast tissue compared to that older technique — it doesn't eliminate the risk, but the toxicity-avoidance argument for omission is meaningfully weaker against current technique than against the studies that established it.
After the discussion of modern radiotherapy technique's reduced toxicity profile, the team leaned toward offering radiotherapy omission given her PET-negative status and her own stated priorities around long-term treatment burden — but this was explicitly framed to her as a preference-sensitive decision between two reasonable paths, not a clear evidence-based winner.
The team did not reach a unanimous recommendation. She was given full counseling on both the relapse-rate difference and the long-term toxicity data, including how modern radiotherapy technique changes that toxicity calculation, and asked to decide for herself which trade-off she wanted to accept. As of this visit, that decision is hers to make, not the team's to hand her.